The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the ...

FDA delays Bayer’s elinzanetant review to Oct 2025 amid liver safety concerns; global approvals still on track.

Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) shares traded higher in Germany on Friday after the company lifted its full-year guidance ...